Sinoway Medical: The company's daily operations are normal, with no major adjustments in the market environment and industry policies. There are no undisclosed material events that should be disclosed by major shareholders, etc.

From August 20th to 22nd, 2025, the closing price of Seno Medical's stock deviated by 30% for three consecutive trading days, indicating abnormal fluctuations. After a self-inspection, the company's daily operations were found to be normal, with no significant adjustments in market conditions or industry policies, and no undisclosed major issues involving the controlling shareholder. As of August 22nd, the company's stock price was 32.70 yuan per share, with recent significant fluctuations, a rolling P/E ratio of 2318.77, significantly deviating from the industry average, and a higher turnover rate than before. In addition, a subsidiary's product has received FDA breakthrough medical device designation, but this does not guarantee registration approval, and uncertainties remain regarding future market listing; although the blood flow-guided mesh stent has won bids and procurement projects, sales volume cannot be predicted.